UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [ 14 C ] encorafenib in healthy male subjects

Pharmacology research & perspectives, 2023-10, Vol.11 (5), p.e01140-e01140

2023

Volltextzugriff (PDF)

Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations

Clinical and translational science, 2023-12, Vol.16 (12), p.2675-2686

2023

Volltextzugriff (PDF)

Immobilized Cytochrome P450 for Monitoring of P450-P450 Interactions and Metabolism

Drug metabolism and disposition, 2016-05, Vol.44 (5), p.741-749

2016

Volltextzugriff (PDF)

Esterase Activities in the Blood, Liver and Intestine of Several Preclinical Species and Humans

Drug metabolism letters, 2009-04, Vol.3 (2), p.70-77

2009

Volltextzugriff (PDF)

Measurement of Electron Transfer through Cytochrome P450 Protein on Nanopillars and the Effect of Bound Substrates

Journal of the American Chemical Society, 2013-03, Vol.135 (10), p.3834-3840

2013

Volltextzugriff (PDF)

Use of Immobilized Cytochrome P4502C9 in PMMA-Based Plug Flow Bioreactors for the Production of Drug Metabolites

Applied biochemistry and biotechnology, 2014-02, Vol.172 (3), p.1293-1306

2014

Volltextzugriff (PDF)

Selective filling of nanowells in nanowell arrays fabricated using polystyrene nanosphere lithography with cytochrome P450 enzymes

Nanotechnology, 2012-09, Vol.23 (38), p.385101-1-9

2012

Volltextzugriff (PDF)

Pharmacodynamic Variability beyond That Explained by MICs

Antimicrobial Agents and Chemotherapy, 2013-04, Vol.57 (4), p.1730-1735

2013

Volltextzugriff (PDF)

Electrocatalytic drug metabolism by CYP2C9 bonded to a self-assembled monolayer-modified electrode

Drug metabolism and disposition, 2009-04, Vol.37 (4), p.892-899

2009

Volltextzugriff (PDF)

Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo–In Vitro–In Silico Approach

Molecular pharmaceutics, 2023-05, Vol.20 (5), p.2589-2599

2023

Volltextzugriff (PDF)

An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)

Clinical pharmacology: advances and applications, 2015-01, Vol.7 (default), p.87-95

2015

Volltextzugriff (PDF)

Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors

Cancer chemotherapy and pharmacology, 2024-09, Vol.94 (3), p.337-347

2024

Volltextzugriff (PDF)

Novel Pharmacodynamic Approach to Assess Obatoclax (GX15-070) and Bortezomib (BTZ) Synergism in Non-Hodgkin’s Lymphoma

Clinical cancer drugs, 2015-05, Vol.2 (1), p.44-53

2015

Volltextzugriff (PDF)

Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration

Clinical pharmacokinetics, 2024-04, Vol.63 (4), p.483-496

2024

Volltextzugriff (PDF)

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2671-TPS2671

2021

Volltextzugriff (PDF)

Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy

Journal of medicinal chemistry, 2024-08, Vol.67 (16), p.14466-14477

2024

Volltextzugriff (PDF)

A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors

Clinical cancer research, 2020-10, Vol.26 (19), p.5102-5112

2020

Volltextzugriff (PDF)

Self-Organized Honeycomb Structures of Mn 12 Single-Molecule Magnets

The journal of physical chemistry. B, 2009-11, Vol.113 (44), p.14674-14680

2009

Volltextzugriff (PDF)

Self-Organized Honeycomb Structures of Mn12 Single-Molecule Magnets

The journal of physical chemistry. B, 2009-11, Vol.113 (44), p.14674-14680

2009

Volltextzugriff (PDF)

A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600 -mutant solid tumors and melanoma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9518-9518

2017

Volltextzugriff (PDF)

Abstract 3709: Synergistic effects of obatoclax (GX15-070) and bortezomib (BTZ) in non-Hodgkin's lymphoma

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3709-3709

2012

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(30)
Dissertationen
(1)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(13)
Humans
(9)
Pharmacology & Pharmacy
(8)
Pharmacokinetics
(6)
Animals
(5)
Drug Dosages
(5)
Mice
(5)
Mutation
(5)
Drug Interactions
(4)
Antineoplastic Agents - Pharmacology
(3)
Antineoplastic Agents - Therapeutic Use
(3)
Biological And Medical Sciences
(3)
Cell Line, Tumor
(3)
Chemistry
(3)
Clinical Trials
(3)
Colorectal Cancer
(3)
Cytochrome P-450 Enzyme System - Metabolism
(3)
Kinases
(3)
Male
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [ 14 C ] encorafenib in healthy male subjects

Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations

Immobilized Cytochrome P450 for Monitoring of P450-P450 Interactions and Metabolism

Esterase Activities in the Blood, Liver and Intestine of Several Preclinical Species and Humans

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

Measurement of Electron Transfer through Cytochrome P450 Protein on Nanopillars and the Effect of Bound Substrates

Use of Immobilized Cytochrome P4502C9 in PMMA-Based Plug Flow Bioreactors for the Production of Drug Metabolites

Selective filling of nanowells in nanowell arrays fabricated using polystyrene nanosphere lithography with cytochrome P450 enzymes

Pharmacodynamic Variability beyond That Explained by MICs

Electrocatalytic drug metabolism by CYP2C9 bonded to a self-assembled monolayer-modified electrode

Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo–In Vitro–In Silico Approach

An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)

Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors

Novel Pharmacodynamic Approach to Assess Obatoclax (GX15-070) and Bortezomib (BTZ) Synergism in Non-Hodgkin’s Lymphoma

Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors

Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy

A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Self-Organized Honeycomb Structures of Mn 12 Single-Molecule Magnets

Self-Organized Honeycomb Structures of Mn12 Single-Molecule Magnets

A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600 -mutant solid tumors and melanoma

Identification of the Clinical Development Candidate MRTX849 , a Covalent KRAS G12C Inhibitor for the Treatment of Cancer

Abstract 3709: Synergistic effects of obatoclax (GX15-070) and bortezomib (BTZ) in non-Hodgkin's lymphoma

Suchergebnisse filtern